Par Drugs and Chemicals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Par Drugs and Chemicals için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.7%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Oct 29

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Par Drugs and Chemicals yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:PAR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	1,041	183	145	172	N/A
6/30/2024	953	146	N/A	N/A	N/A
3/31/2024	956	145	142	202	N/A
12/31/2023	973	142	N/A	N/A	N/A
9/30/2023	962	127	140	227	N/A
6/30/2023	952	115	N/A	N/A	N/A
3/31/2023	957	113	57	134	N/A
12/31/2022	933	103	N/A	N/A	N/A
9/30/2022	873	106	32	76	N/A
6/30/2022	821	91	N/A	N/A	N/A
3/31/2022	751	92	44	76	N/A
12/31/2021	692	112	N/A	N/A	N/A
9/30/2021	686	112	4	67	N/A
6/30/2021	631	115	N/A	N/A	N/A
3/31/2021	608	116	70	121	N/A
12/31/2020	579	88	N/A	N/A	N/A
9/30/2020	550	83	102	120	N/A
6/30/2020	554	65	82	98	N/A
3/31/2020	558	48	61	77	N/A
12/31/2019	532	41	N/A	N/A	N/A
9/30/2019	506	20	12	17	N/A
6/30/2019	484	23	15	19	N/A
3/31/2019	463	25	30	34	N/A
3/31/2018	424	15	N/A	46	N/A
3/31/2017	488	18	N/A	92	N/A
3/31/2016	333	4	N/A	65	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PAR 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: PAR 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: PAR şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: PAR şirketinin gelirinin Indian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: PAR şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PAR 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Par Drugs and Chemicals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Investor sentiment improves as stock rises 35%

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Second quarter 2025 earnings released: EPS: ₹6.99 (vs ₹3.97 in 2Q 2024)

CEO & Executive Director recently sold ₹23m worth of stock

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 21, 2024

First quarter 2025 earnings released: EPS: ₹2.06 (vs ₹2.01 in 1Q 2024)

Full year 2024 earnings released: EPS: ₹11.78 (vs ₹9.21 in FY 2023)

Now 23% overvalued after recent price rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.52 in 3Q 2023)

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Second quarter 2024 earnings released: EPS: ₹3.97 (vs ₹3.03 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 15%

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 16, 2023

First quarter 2024 earnings released: EPS: ₹2.01 (vs ₹1.86 in 1Q 2023)

Investor sentiment improves as stock rises 23%

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Full year 2023 earnings released: EPS: ₹9.21 (vs ₹7.49 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.72 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.03 (vs ₹1.80 in 2Q 2022)

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.86 (vs ₹1.90 in 1Q 2022)

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 10, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹7.49 (vs ₹9.44 in FY 2021)

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Non Executive Director recently bought ₹304k worth of stock

CEO & Executive Director recently bought ₹313k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

CEO & Executive Director recently bought ₹199k worth of stock

CEO & Executive Director recently bought ₹189k worth of stock

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹1.25 per share

Second quarter 2022 earnings released: EPS ₹1.80 (vs ₹2.08 in 2Q 2021)

Investor sentiment deteriorated over the past week

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Full year 2021 earnings released: EPS ₹9.44 (vs ₹3.87 in FY 2020)

Investor sentiment improved over the past week

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Investor sentiment improved over the past week

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Investor sentiment improved over the past week

New 90-day high: ₹73.40

CEO & Executive Director recently bought ₹391k worth of stock

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Chairman of the Board & MD recently bought ₹263k worth of stock

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Investor sentiment improved over the past week

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Market bids up stock over the past week

New 90-day high: ₹55.90

New 90-day high: ₹51.00

New 90-day high: ₹50.45

New 90-day high - ₹50.00

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin